drugset / Trial / NCT04058145
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
Phase 2
Withdrawn
Massachusetts General Hospital
AperiSys, Inc · collabMerck Sharp & Dohme LLC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This research is studying the safety and effectiveness of AMD3100 and pembrolizumab in participants with metastatic head and neck squamous cell carcinoma.
Timeline
- Start
- 2019-09-30
- Primary completion
- 2019-10-11
- Completion
- 2019-10-11
Outcome
Outcome not reported
Stopped (Business): “Funding Withdrawn”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMD3100 | Small molecule | — | Subcutaneous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |